QIAGEN is launching the QCI enhancements this week at the AMP 2017 Annual Meeting in Salt Lake City, Utah.
First bioinformatics solution integrating new AMP/ASCO/CAP standards for NGS cancer testing to confidently and quickly report clinical relevance of somatic mutations |
| [15-November-2017] |
| HILDEN, Germany, and GERMANTOWN, Maryland, November 15, 2017 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today launched enhancements in its QIAGEN Clinical Insight (QCI) bioinformatics software automating the AMP/ASCO/CAP Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer, advancing precision medicine with the first solution to offer molecular pathologists critical information needed to guide oncologists’ treatment decisions. Leading oncology and pathology groups published the guidelines in January 20171 in response to growing clinical implementation of next-generation sequencing (NGS) for genetic profiling of cancers. QIAGEN’s QCI-Interpret software integrates the consensus standards with a comprehensive biomedical knowledge base on potential treatments and clinical trials, guiding the selection of treatments based on the findings from each patient’s genomic testing and diagnosis. QIAGEN is launching the QCI enhancements this week at the Association for Molecular Pathology (AMP) 2017 Annual Meeting in Salt Lake City, Utah. Click here [https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-15-QCI_AMP?sc_lang=en ] for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-15-QCI_AMP?sc_lang=en Contacts: QIAGEN Investor Relations John Gilardi +49-2103-29-11711 e-mail: ir@QIAGEN.com Public Relations Dr. Thomas Theuringer +49-2103-29-11826 e-mail: pr@QIAGEN.com
SOURCE QIAGEN | ||
Company Codes: Frankfurt:QIA, NASDAQ-NMS:QGEN, Bloomberg:QGEN@US, Bloomberg:QIA@GR, RICS:QGEN.F, ISIN:NL0000240000 |
